《新股消息》未盈利生科企和铂医药递上市申请
未盈利的内地生物制药企业和铂医药递交上市申请,保荐人为摩根士丹利、美国银行及中信证券。
初步文件显示,和铂医药从事研究及开发免疫与肿瘤疾病领域的新型及高度差异化抗体疗法,截至2020年6月30日已有六个项目进入临床阶段。由於尚未有产品获准进行商业销售,因此该公司未从产品销售产生任何收益,於2018年及2019年年度录经营亏损3,460万美元及6,750万美元,并於今年上半年蚀4,840万美元。
和铂医药上月宣布,已完成1.03亿美元C轮融资,该次融资由Hudson Bay Capital领投,碧桂园(02007.HK)碧桂园创投、奥博资本、高特佳投资集团、锐智资本等参投。招股资料显示,GIC、国寿成达、联想控股旗下正奇金融等,亦为公司上市前投资者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.